Citations

Clear

1031 citation(s) found for "Clark, AS".

Abstract PD1-10: Evaluation of SGN-LIV1a followed by AC in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL
Beckwith, Heather , Schwab, Richard J. , Stringer-Reasor, Erica , Wei, Shi , Chien, A. Jo , Albain, Kathy S. , Clark, Amy S. , Han, Heather, Nanda, Rita, Sanft, Tara , Perlmutter, Jane , Melisko, Michelle , Veer, Laura J. van’t , Wilson, Amy , Asare, Smita , Sanil, Ashish, Berry, Donald A. , Schwab, Richard, Yau, Christina , Kalinsky, Kevin M. , Wallace, Anne M. , Elias, Anthony , Yee, Douglas , Boughey, Judy C. , Isaacs, Claudine , Mitri, Zahi Ibrahim , Lang, Julie E. , Thomas, Alexandra , DeMichele, Angela , Rugo, Hope S. , Hylton, Nola M. , Symmans, W. Fraser , Esserman, Laura J.

Mayo Clinic

Cancer Research | February 15, 2021 | Volume: 81 | Issue: 4_Supplement | Pages: PD1-10-PD1-10

10.1158/1538-7445.sabcs20-pd1-10 Get It

Abstract Background: I-SPY 2 is a multicenter, phase 2 trial using response-adaptive randomization within molecular subtypes defined by receptor status and MammaPrint (MP) risk to evaluate novel agents as neoadjuvant therapy for women with high-risk stage II/III breast cancer. The primary endpoint is pathologic complete response (pCR, ypT0/Tis ypN0). SGN-LIV1A is an investigational antibody drug conjugate consisting of an antibody to LIV1A, a zinc transporter highly prevalent in breast cancer, and a highly potent microtubule inhibitor, monomethyl auristatin E. Retrospective IHC analysis of LIV1A expression levels amongst tumor samples from 100 previous ISPY-2 patients showed 88% of breast tumor samples with moderate to high expression of LIV1A (Yau, C. et al SABCS 2018).Methods: Women with tumors ≥ 2.5cm were eligible for screening. Only HER2 negative (HER2-) patients were eligible for this treatment, hormone-receptor positive (HR+) patients had to have MP high molecular profile. Treatment included SGN-LIV1A 2.5 mg/kg (max dose 250 mg) every 3 weeks x 4, followed by doxorubicin/cyclophosphamide (AC) every 2-3 weeks x 4. The control arm was weekly paclitaxel x 12 followed by AC every 2-3 weeks x 4. All patients undergo serial MR imaging where response at 3 & 12 weeks combined with accumulating pCR data are used to estimate, and continuously update, predicted pCR rate for the trial arm. Analysis set was modified intention to treat with patients who switched to non-protocol therapy counted as non-pCR and not as their pCR status at time of surgery. The goal is to identify/graduate regimens with ≥85% Bayesian predictive probability of success (i.e. demonstrating superiority to control) in a future 300-patient phase 3 neoadjuvant trial with a pCR endpoint within signatures defined by HR & HER2 status & MP result. This investigational arm was eligible for graduation in 3 of 10 pre-defined signatures: HER2-, HR+HER2- and HR-HER2-. Regimens may also leave the trial for futility (< 10% probability of success), maximum sample size accrual (10% < probability of success <85%), maximum time in trial (2 years) or for safety as recommended by the independent DSMB. Results: Sixty patients were randomized and evaluable to SGN-LIV1A. The study arm was stopped due to reaching the predetermined time limit for patient accrual of 2 yrs. Final estimated pCR rates are below. The estimated pCR rates were similar between the SGN-LIV1A and control arms for any tumor subtype. Preliminary safety events for SGN-LIV1A include increased rates of transaminitis and hyperglycemia and reduced rates of peripheral neuropathy compared to control. One patient was removed from the analysis as she was determined to have angiosarcoma of the breast. Notably, this patient had a dramatic early response and subsequent pCR to SGN-LIV1A treatment. Conclusion: The value of I-SPY 2 is to give insight about the performance of an investigational agent’s likelihood of achieving pCR. SGN-LIV1A delivered every 3 weeks was comparable to paclitaxel for the primary endpoint of pCR in I-SPY2 and may have a similar side effect profile, however, with less peripheral neuropathy. Clinical trials evaluating weekly dosing of SGN-LIV1A are ongoing. A trial of SGN-LIV1A in the treatment of angiosarcoma is under consideration at this time. Final Estimated pCR Rates and Predictive ProbabilitiesEstimated pCR rate(95% prob interval)SignatureSGN-LIV1AControlProbability SGNLIV1A Superior to ControlPredictive Probability of Success in Phase 3HER2-0.16 (0.08-0.24) N= 600.20 (0.16-0.25) N= 3270.180.02HR-/HER2-0.25 (0.12-0.37) N=360.28 (0.21-0.35) N=1460.310.06HR+/HER2-0.09 (0-0.18) N=240.14 (0.09-0.19) N=1810.150.03 Citation Format: Heather Beckwith, Richard Schwab, Christina Yau, Erica Stringer-Reasor, Shi Wei, A. Jo Chien, Kathy S Albain, Kevin Kalinsky, Anne Wallace, Anthony Elias, Douglas Yee, Amy S Clark, Judy C Boughey, Heather Han, Rita Nanda, Claudine Isaacs, Zahi Mitri, Julie E Lang, Alexandra Thomas, Tara Sanft, Angela DeMichele, Jane Perlmutter, Hope S Rugo, Nola M Hylton, W. Fraser Symmans, Michelle E Melisko, Laura J van't Veer, I-SPY 2 Consortium, Amy Wilson, Smita M Asare, Ashish Sanil, Donald A Berry, Laura J Esserman. Evaluation of SGN-LIV1a followed by AC in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PD1-10.
Statistical Issues in Tumor Marker Studies
Pajak, Thomas F., Clark, Gary M. , Hammond, M. Elizabeth H. , Clark, Gary M., Sargent, Daniel J. , McShane, Lisa M.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | January 28, 2021 | Volume: 124 | Issue: 7 | Pages: 1011-1015

10.5858/2000-124-1011-siitms | PMID 10888777 Get It

Abstract Context. —Inferences from tumor marker studies are complicated by a variety of statistical concerns, which can make proper interpretation of results difficult. This article focuses on important issues that should be addressed when designing, conducting, and analyzing tumor marker studies. Objective. —To highlight the importance of considering statistical significance, risk ratios, statistical power, reproducibility, multiple testing, confirmatory studies, and missing data in the design of marker studies used for prognosis. Results. —Suggestions are provided for more effectively conducting marker studies. These include more careful attention to adequacy of the number of subjects for a marker study and improved documentation and standardization of assay methods. The importance of complete reporting of study results and description of the statistical analysis methods used is also emphasized. Conclusion. —Cooperation among clinicians, laboratory scientists, and statisticians will be required to conduct statistically sound tumor marker studies and to facilitate prioritizing markers for new and confirmatory studies in an environment of limited patient and specimen resources.
Xanthomatous Dermal Changes in a Patient With Locally Advanced Basal Cell Carcinoma Treated Using Vismodegib
Smith, Shane , Clark, Melanie A., Harker-Murray, Amy, Sokumbi, Olayemi , Sokumbi, Olayemi , Clarke, Callisia N.

Mayo Clinic

The American Journal of Dermatopathology | January 27, 2021 | Volume: 43 | Issue: 8 | Pages: 585-587

10.1097/dad.0000000000001849 | PMID 33534208 Get It

Abstract: Basal cell carcinoma (BCC) is the most commonly diagnosed cutaneous cancer in the United States with more than 2.5 million treated annually. Genetic studies have revealed that approximately 90% of BCCs have a mutation in the hedgehog-signaling pathway. Patients with BCC usually have an excellent prognosis with surgical modalities, however, patients with locally advanced BCC may potentially experience significant cosmetic or functional impairment, with only surgical intervention. Vismodegib is a hedgehog pathway inhibitor that has been successful in treating patients with locally advanced BCC. We report a patient with BCC with a good response to vismodegib and a novel xanthomatous change in the excision specimen.
Immersion learning at an aphasia camp: Analysing student video reflections
Sather, Thomas , Homolka, Terah, Clark, Mary Beth, Sather, Thomas W, Hoepner, Jerry K.

Mayo Clinic

International Journal of Speech-Language Pathology | January 27, 2021 | Volume: 23 | Issue: 4 | Pages: 430-440

10.1080/17549507.2020.1844294 | PMID 33501863 Get It

A Longitudinal Evaluation of Speech Rate in Primary Progressive Apraxia of Speech
Utianski, Rene L. , Martin, Peter R. , Hanley, Holly , Botha, Hugo , Clark, Heather M. , Whitwell, Jennifer L. , Josephs, Keith A. , Utianski, Rene L , Botha, Hugo , Clark, Heather M , Duffy, Joseph R. , Whitwell, Jennifer L.

Mayo Clinic

Journal of Speech, Language, and Hearing Research | January 21, 2021 | Volume: 64 | Issue: 2 | Pages: 392-404

10.1044/2020_jslhr-20-00253 | PMID 33476188 Get It

Purpose Individuals with primary progressive apraxia of speech (PPAOS) have apraxia of speech (AOS) in which disruptions in articulation or prosody predominate the speech pattern, referred to, respectively, as phonetic or prosodic subtypes. Many develop aphasia and/or dysarthria. Past research has demonstrated that simple temporal acoustic measures are sensitive to the presence of AOS. The aim of this study was to describe the change in temporal acoustic measures over time and assess if specific patterns of AOS or co-occurring aphasia or dysarthria impact the rate of change over time. Method Durations for multiple productions of the words cat , catnip , catapult , and catastrophe , in an imitative speech task, were recorded for 73 patients, with two to six visits each. A linear mixed-effects model was used to assess the cross-sectional differences and longitudinal influence of AOS subtype and presence of aphasia/dysarthria on speech rate. Pearson correlations were calculated between rate measures and performance on other clinical measures. Results Cross-sectionally, patients with prosodic-predominant PPAOS produced words more slowly than those with phonetic-predominant PPAOS. Patients with either aphasia or dysarthria produced words more slowly than those without. Longitudinally, the speech rate of patients with phonetic-predominant PPAOS had a reduction of 0.5 syllables per second per year. Patients with prosodic-predominant AOS changed less quickly, as did those who developed aphasia. Dysarthria did not impact rate of change. There were strong associations between speech rate measures and other clinical indices of speech and language functioning. Conclusion Simple temporal acoustic measures may reflect the subtype of AOS (phonetic or prosodic predominant), serve as an index of progression of AOS, and inform prognostication relative to the presenting combination of speech and language features. Supplemental Material https://doi.org/10.23641/asha.13564724
Identifying seizure risk factors: A comparison of sleep, weather, and temporal features using a Bayesian forecast
Payne, Daniel E. , Karoly, Philippa J. , Křemen, Václav , Gerla, Václav , Kuhlmann, Levin , Worrell, Gregory A. , Cook, Mark , Grayden, David B. , Freestone, Dean R. , Karoly, Phillipa J , Kremen, Vaclav , Gerla, Vaclav , Kuhlmann, Levin , Worrell, Gregory A , Cook, Mark J , Grayden, David B , Freestone, Dean R , Dell, Katrina L.

Mayo Clinic

Epilepsia | December 30, 2020 | Volume: 62 | Issue: 2 | Pages: 371-382

10.1111/epi.16785 | PMID 33377501 Get It

AbstractObjectiveMost seizure forecasting algorithms have relied on features specific to electroencephalographic recordings. Environmental and physiological factors, such as weather and sleep, have long been suspected to affect brain activity and seizure occurrence but have not been fully explored as prior information for seizure forecasts in a patient‐specific analysis. The study aimed to quantify whether sleep, weather, and temporal factors (time of day, day of week, and lunar phase) can provide predictive prior probabilities that may be used to improve seizure forecasts.MethodsThis study performed post hoc analysis on data from eight patients with a total of 12.2 years of continuous intracranial electroencephalographic recordings (average = 1.5 years, range = 1.0–2.1 years), originally collected in a prospective trial. Patients also had sleep scoring and location‐specific weather data. Histograms of future seizure likelihood were generated for each feature. The predictive utility of individual features was measured using a Bayesian approach to combine different features into an overall forecast of seizure likelihood. Performance of different feature combinations was compared using the area under the receiver operating curve. Performance evaluation was pseudoprospective.ResultsFor the eight patients studied, seizures could be predicted above chance accuracy using sleep (five patients), weather (two patients), and temporal features (six patients). Forecasts using combined features performed significantly better than chance in six patients. For four of these patients, combined forecasts outperformed any individual feature.SignificanceEnvironmental and physiological data, including sleep, weather, and temporal features, provide significant predictive information on upcoming seizures. Although forecasts did not perform as well as algorithms that use invasive intracranial electroencephalography, the results were significantly above chance. Complementary signal features derived from an individual's historic seizure records may provide useful prior information to augment traditional seizure detection or forecasting algorithms. Importantly, many predictive features used in this study can be measured noninvasively.
Initial Derivation of Positive Dementia-Related Observational Measures: A Descriptive Ethnography
Staehler, Maya, Benson, Clark , Madden, Jordan, Block, Laura , Gilmore‐Bykovskyi, Andrea L

Mayo Clinic

Innovation in Aging | December 17, 2020 | Volume: 4 | Issue: Supplement_1 | Pages: 164-164

10.1093/geroni/igaa057.531 Get It

Abstract Person-centered caregiving approaches emphasize efforts to protect and maintain the personhood of people living with dementia (PLWD). The influence on person-centered caregiving approaches on PLWD have predominantly focused on deficit-oriented outcomes, such as absence or reduction of behavioral symptoms. While important to quality of life, the absence of measurable “positive” responses to person-centered caregiving approaches limit opportunities to specify sensitive and meaningful outcome measures that more holistically represent PLWD’s care experiences as more than the absence of a negative outcome. To address these gaps, we conducted a secondary analysis of video-observations of PLWD (N=9) surrounding mealtime cares using a descriptive ethnographic approach. Our objectives were to descriptively summarize specific responsive behaviors demonstrated by PLWD surrounding person-centered caregiving interactions, specifying observable features of these responses and consider their utility in future video-observational research. Findings indicate PLWD contribute both verbal and non-verbal communication surrounding person-centered approaches which can be characterized as conversational (starting conversation, answering or asking questions), expressing preferences (indicating needs and preferences, agreeing or disagreeing, complying with or refusing caregiver requests, permission granting), emotional responses (mirroring caregivers’ emotions, demonstrating emotion e.g. smiling), and reflexive (mirroring of caregiver’s actions), with overlap between categories. Findings suggest that PLWD not only contribute and respond in meaningful ways to person-centered interactions, but also initiate a significant number of these interactions. This study contributes to a growing body of research and advocacy that examines the personhood and abilities of PLWD and establishes the utility of observational data in studying PLWD contributions.
Obstetric Anesthetic Management for Parturients with Hereditary Angioedema: A Case Report and Suggested Protocol
Clark, Kathryn J. , Sviggum, Hans P. , Jacob, Adam K. , Volcheck, Gerald W., Szymanski, Linda M. , Clark, Kathryn , Arendt, Katherine W. , Sharpe, Emily E.

Mayo Clinic

Pain Medicine | December 9, 2020 | Volume: 22 | Issue: 8 | Pages: 1878-1882

10.1093/pm/pnaa457 | PMID 33769522 Get It

Abstract Hereditary angioedema (HAE) is a disease manifested by repeated episodes of localized submucosal or subcutaneous edematous episodes, potentially triggered by emotional stress, mechanical trauma, or intake of estrogens. We present our experience managing two parturients with HAE. Multidisciplinary care is essential for planning and executing the specialized care of these patients, and management included extensive planning among obstetric, anesthesiology, and allergy and immunology teams. Pregnancy has been shown to have a variable effect on triggering HAE episodes. First-line treatment includes C1 esterase inhibitor concentrate, which can also be used for prophylaxis in high-risk patients. Neuraxial analgesia is recommended to avoid general anesthesia and was established early in both individuals. Vaginal delivery was well tolerated without need for emergent treatment for angioedema symptoms.
Network electroencephalographic (EEG) measures in primary progressive apraxia of speech and aphasia
Caviness, John N., Whitwell, Jennifer , Josephs, Keith A. , Utianski, Rene L. , Botha, Hugo , Worrell, Gregory A. , Duffy, Joseph R. , Clark, Heather M.

Mayo Clinic

Alzheimer's & Dementia | December 7, 2020 | Volume: 16 | Issue: S5 | Pages: No page available

10.1002/alz.039056 Get It

AbstractBackgroundPast research has demonstrated that clinical EEG is sensitive to dementia associated with Alzheimer's (AD) and Parkinson’s diseases (PD), and nonfluent/agrammatic Primary Progressive Aphasia (agPPA), but not Primary Progressive Apraxia of Speech (PPAOS). However, clinical EEG studies do not quantify interactions of multiple brain areas, or network activity. Graph theory (GT) simplifies analyzing and comparing complex brain networks. Studies have shown changes in EEG GT measures in AD and PD, but have not been studied in agPPA or PPAOS. The goal of this study was to use GT to characterize network‐level changes and associations with speech and language functioning in patients with agPPA and PPAOS.MethodsScalp EEGs of 14 agPPA and 7 PPAOS patients were collected during relaxed wakefulness (10‐20 positions, 256Hz sampling, 1–200Hz bandpass filter). Eight artifact‐free epochs were selected from non‐overlapping 1024‐point epochs. Via Brainwave software, GT weighted connectivity and minimum spanning tree (MST) measures were calculated for theta and alpha frequency bands. Differences in theta MST measures between agPPA and PPAOS were assessed with Wilcoxon rank‐sum tests. Spearman correlations were computed between behavioral and all network measures across all patients.ResultsTheta frequency MST diameter and eccentricity were significantly lower and leaf was significantly higher in agPPA compared to PPAOS patients; betweenness centrality did not differ. This indicates agPPA networks are more integrated (star‐like) than PPAOS. There were significant correlations between several network measures (e.g. kappa, lambda, PLI) and indices of speech‐language functioning.ConclusionsThe results provide EEG evidence of network alteration in agPPA and PPAOS patients. The GT measures and associations with behavioral measures provide support for reduced global efficiency, or network specificity, in these patients. The correlation of language measures with lambda (path length) in the theta frequency band suggests agPPA is associated with an inefficient path length and/or increased integration. The correlation between apraxia of speech (AOS) measures and MST eccentricity in the alpha frequency band suggests that more severe AOS is associated with reduced distance between two nodes. This study demonstrates potential for EEG GT measures to quantify network changes and distinguish network changes between related but different clinical syndromes.
TAMI-28. DIFFERENTIAL MIGRATION MECHANICS AND IMMUNE RESPONSES OF GLIOMA SUBTYPES
Liu, Chao , Braman, Brooke C , Rathe, Susan K. , Sarver, Aaron L. , Ghaderi, Nima, McMahon, Mariah, Klank, Rebecca, McFarren, Joey, Clark, H. Brent , Rosenfeld, Steven S. , Largaespada, David A. , Shamsan, Ghaidan A , Rathe, Susan K. , McMahon, Mariah , Klank, Rebecca L. , Tschida, Barbara R , Sarkaria, Jann N. , Clark, H Brent , Largaespada, David A. , Odde, David J

Mayo Clinic

Neuro-Oncology | December 4, 2020 | Volume: 22 | Issue: Supplement_2 | Pages: ii219-ii219

10.1093/neuonc/noaa215.916 Get It

Abstract In Glioblastoma (GBM), tumor spreading is driven by tumor cells’ ability to infiltrate healthy brain parenchyma, which prevents complete surgical resection and contributes to tumor recurrence. GBM molecular subtypes, classical, proneural and mesenchymal, were shown to strongly correlate with specific genetic alterations (Mesenchymal: NF1; Classical: EGFRVIII; Proneural: PDGFRA). Here we tested the hypothesis that a key mechanistic difference between GBM molecular subtypes is that proneural cells are slow migrating and mesenchymal cells are fast migrating. Using Sleeping Beauty transposon system, immune-competent murine brain tumors were induced by SV40-LgT antigen in combination with either NRASG12V (NRAS) or PDGFB (PDGF) overexpression. Cross-species transcriptomic analysis revealed NRAS and PDGF-driven tumors correlate with human mesenchymal and proneural GBM, respectively. Similar to human GBM, CD44 expression was higher in NRAS tumors and, consistent with migration simulations of varying CD44 levels, ex vivo brain slice live imaging showed NRAS tumors cells migrate faster than PDGF tumors cells (random motility coefficient = 30µm2/hr vs. 2.5µm2/hr, p < 0.001). Consistent with CD44 function as an adhesion molecule, migration phenotype was independent of the tumor microenvironment. NRAS and human PDX/MES tumor cells were found to migrate faster and have larger cell spread area than PDGF and human PDX/PN tumors cells, respectively, in healthy mouse brain slices. Furthermore, traction force microscopy revealed NRAS tumor cells generate larger traction forces than PDGF tumors cells which further supports our theoretical mechanism driving glioma migration. Despite increased migration, NRAS cohort had better survival than PDGF which was attributed to enhanced antitumoral immune response in NRAS tumors, consistent with increased immune cell infiltration found in human mesenchymal GBM. Overall our work identified a potentially actionable difference in migration mechanics between GBM subtypes and establishes an integrated biophysical modeling and experimental approach to mechanically parameterize and simulate distinct molecular subtypes in preclinical models of cancer.